Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie (prior sponsor, Abbott)
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The subject was randomized into Study M06-855 and completed treatment in Periods 1 and 2 and the 2-week Extension Period
If female, subject must be either postmenopausal for at least 1 year, surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or practicing at least a method of birth control throughout the study
If female, the result of a pregnancy tests are negative
The subject is judged to be in generally good health
You may not be if
More than 7 days have elapsed since the last dose of study drug in Study M06-855
The subject has taken any ADHD medication between the last dose of study drug in Study M06-855 and the first dose of study drug in the current study
The subject anticipates a move outside the geographic area
Clareo Health | A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)
